Molecular analysis of the integrons of metallo-β-lactamase-producing *Pseudomonas aeruginosa* isolates collected by nationwide surveillance programs across Japan

Yoko Mano¹, Tomoo Saga¹, Yoshikazu Ishii¹*, Ayumi Yoshizumi¹, Robert A Bonomo²,³, Keizo Yamaguchi¹ and Kazuhiro Tateda¹

Abstract

**Background:** We investigate the evolving molecular epidemiology of metallo-β-lactamase (MBL)-producing *Pseudomonas aeruginosa* isolates collected in a 100 institution, nationwide surveillance study in Japan from 2004 to 2006.

**Results:** MBL-producers were detected in 23/996 isolates (2.3%) in 2004 and 21/992 (2.1%) in 2006. Antimicrobial resistance (specifically, carbapenem resistance) rates between two periods did not differ significantly. MBL-producers were more prevalent in urinary tract isolates. *bla*<sub>IMP-1</sub> group was the most predominant (38 isolates, 80%), followed by 3 *bla*<sub>IMP-7</sub>, 2 *bla*<sub>IMP-11</sub> group, and 1 *bla*<sub>VIM-1</sub>. All MBL genes were identified in 16 different class 1 integrons, most of which were novel to INTEGRALL database. A total of 17 isolates of sequence type (ST) 235, a recognized worldwide drug-resistant lineage, were distributed in 5 geographic regions across Japan. ST235 isolates included a sublineage associated with In113-like integron. ST357 was identified in 14 isolates, 9 of which harboring a sole *bla*<sub>IMP-1</sub> gene cassette (In994) were recovered from Chugoku region in 2004. ST357 isolates with *bla*<sub>IMP-11</sub> group or ST235 with *bla*<sub>VIM-1</sub> emerged in 2006. We also report for the first time the presence of novel *fosI* gene cassette in strains other than *Mycobacterium* spp.

**Conclusions:** Our data give an important “snapshot” of the molecular characteristics and dynamics of MBL-producing lineages in *P. aeruginosa* in Japan. The significant association of specific genotypes and integrons implies that dissemination and transmission of the preexisting resistant lineage, rather than horizontal gene transfer in situ, might largely explain their endemicity.

**Keywords:** Metallo-β-lactamases, Integron, *Pseudomonas aeruginosa*

**Background**

As carbapenems are among the most reliable therapeutic options for treating *Pseudomonas aeruginosa* infection, the finding of carbapenem resistance is an ominous development that challenges this “last resort antibiotic”. Production of metallo-β-lactamas (MBLs) is an important mechanism of carbapenem resistance, not only because MBLs can hydrolyse most β-lactams including carbapenems, but MBL-producing *P. aeruginosa* are frequently also multidrug-resistant (resistant to ≥3 classes) [1]. More importantly, *bla*<sub>MBL</sub> genes are often located in the gene cassette (GC) arrays in integrons, where multiple resistant determinants against antimicrobials or disinfectants are accumulated, and can be horizontally transferred [2].

Multilocus sequence typing (MLST), a genotyping method based on nucleotide sequencing of several house-keeping genes in the bacterial chromosome, has been increasingly applied for epidemiological investigation of pathogenic microorganisms [3]. In *P. aeruginosa*
isolation, international clones such as ST (sequence type) 235, ST244, ST175, and ST357 are reported to have widespread dissemination [4-11]. Most notably, ST235 and their close variants (e.g., clonal complex 235) appear prominent in multiple-drug resistance.

Recently, the INTEGRALL database was developed for providing a systematic nomenclature for integrons [12]; these genetic elements can be potentially shared by a wide range of microorganisms as a result of horizontal gene transfer [13]. Moreover, GC arrays of integrons could be excised or integrated by the action of integrases and therefore be more diverse [2]. Therefore, INTEGRALL is expected to facilitate our comprehensive understanding of the complexity and development of integron-mediated drug resistance.

In Japan, as many as 80-90% of the MBL-producing P. aeruginosa were reported to be resistant to carbapenems, aminoglycosides, and quinolones [14,15]. Notably, several molecular epidemiological surveys report the increasing prevalence of multidrug-resistant P. aeruginosa (MDRP); in these the predominance of IMP-type MBL genes as well as ST235 and ST357 among MDRP is documented [15-20]. Although the prevalence of MBL among P. aeruginosa clinical isolates was reported as 2-4% [21,22], molecular epidemiology of MBL-producing P. aeruginosa in consecutive nationwide surveillance programs has not been analysed.

In the current study, we conducted a molecular epidemiological survey of the genetic context of MBL-producing P. aeruginosa isolates collected by nationwide surveillance. Our data not only provide an important “snapshot” of the molecular characteristics and dynamics of MBL-producing predominant lineages including ST235 and ST357, but also provide important baseline information for future surveillance programs. (This work was presented in part at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011.)

Results and discussion
Antimicrobial susceptibility of MBL-producing P. aeruginosa isolates
In the present study, 44 MBL-producing P. aeruginosa isolates were identified (Table 1); these were recovered from 6 out of 8 geographic regions across Japan. The number of isolates is comparable in 2004 and in 2006. MBL-producers were isolated more frequently from urinary tract specimens than from other specimens (24/408 vs. 20/1580; P < 0.0001). Although this trend was consistent with the previous reports in Japan [23], the reason for preference of MBL-producers for urinary tract was not addressed in this study where we did not analyse non-MBL-producers.

All MBL-producers met the international criteria for MDRP (Table 2). Overall, the antibiotic resistance patterns of MBL-producers did not differ significantly among the isolates between 2004 and 2006, except in cases where piperacillin was tested (4/23 resistant to piperacillin in 2004 vs 16/21 in 2006; P = 0.0002). Although this result reinforces the impact of the MBL production in MDRP, their limited susceptibility to the entire armamentarium of β-lactams including piperacillin or aztreonam, which MBLs are expected to hydrolyse less efficiently, suggests the involvement of multiple factors contributing to their drug resistance [24].

Acknowledging that CLSI breakpoints were not available, the majority of MBL-producers showed increased susceptibility to arbekacin (MIC >8 μg/ml in only 5 strains, 11%). Although further investigation is needed, this agent might be a candidate for consideration as a therapeutic agent [25]. For more than two decades in Japan, arbekacin is a commercially available aminoglycoside effective against methicillin-resistant Staphylococcus aureus infections and its use in Gram negative infections is being explored.

MBL genes and class 1 integrons among MBL-producing P. aeruginosa
Among MBL-producing P. aeruginosa isolates, seven different MBL genes were identified. The most prevalent was blaIMP-1 group found in 38 isolates (80%) (31 blaIMP-1, 5 blaIMP-10, and 2 blaIMP-6), followed by 3 blaIMP-7, 2 blaIMP-11 group (1 blaIMP-11 and 1 blaIMP-41), and 1 blaVIM-1, as anticipated (Table 2) [15-19]. While blaIMP-1 and blaIMP-10 were found both in 2004 and 2006, blaIMP-7, blaIMP-11, and blaIMP-41 emerged in 2006.

All MBL-producing isolates possessed intI1, and all MBL genes were located in the GC arrays of class 1 integron (Table 2); 16 distinct MBL-harbor ing integrons were identified. Complete GC arrays of all integrons except one were successfully sequenced, as many as 13 of which were novel to INTEGRALL database. Fifteen isolates harbored In113-like integrons, which consisted of 3 GCs, namely blaIMP-1 group cassette (blaIMP-1 in In113,
| No. | Year | Location   | Specimens        | PFGE | ST     | Integron                      | MIC (μg/ml)                |
|-----|------|------------|------------------|------|--------|-------------------------------|---------------------------|
|     |      |            |                  |      |        |                               | PIPC | CAZ | CFPM | AZT | IPM | AMK | ABK | CPFX |
| 4046| 2004 | Shikoku    | Urine            | A    | 1070   | In113 | blαIMP-1 | aacA28 | aadA1 | 32   | >512 | >512 | 32  | 512 | 256 | 4   | 16   |
| 3986| 2006 | Kanto      | Urine            | C    | 235    | (partial) | blαIMP-3 | aadA1 | 128  | 512  | 256  | 8   | 64  | >512 | 32  | 16   |
| 3995| 2006 | Kanto      | Urine            | C    | 235    | (partial) | blαIMP-3 | aadA1 | 256  | >512 | 256  | 8   | 64  | >512 | 64  | 16   |
| 3997| 2006 | Kanto      | Purulent discharge| C   | 235    | (partial) | blαIMP-1 | aadA1 | 8    | >512 | 256  | 4   | 512 | >512 | 64  | 32   |
| 3988| 2006 | Kinki      | Urine            | A    | 235    | In113  | blαIMP-1 | aadA1a| 256  | >512 | >512 | 64  | 64  | 256  | 2   | 32   |
| 3977| 2006 | Hokkaido   | Feces            | B    | 235    | In113  | blαIMP-1 | aadA1a| 128  | 512  | 512  | 16  | 128 | 256  | 2   | 32   |
| 3978| 2006 | Chugoku    | Drain            | B    | 235    | In113  | blαIMP-1 | aadA1a| 256  | >512 | >512 | 64  | 64  | >512 | 4   | 32   |
| 3984| 2006 | Kanto      | Urine            | B    | 235    | In113  | blαIMP-1 | aadA1a| 8    | >512 | 256  | 8   | 64  | >512 | 4   | 16   |
| 3989| 2006 | Kanto      | Urine            | B    | 235    | In113  | blαIMP-1 | aadA1a| 128  | >512 | 256  | 8   | 64  | >512 | 4   | 16   |
| 3990| 2006 | Kanto      | Urine            | B    | 235    | In113  | blαIMP-1 | aadA1a| 256  | >512 | >512 | 64  | 64  | >512 | >128|
| 3991| 2006 | Kanto      | Urine            | B    | 235    | In113  | blαIMP-1 | aadA1a| 128  | >512 | >512 | 64  | 64  | >512 | >128|
| 3995| 2006 | Shikoku    | Pharyngeal mucus | D   | 357    | In826  | aacA7 | fosI | blαIMP-1 | qacG | 8    | >512 | 512  | 8   | 256 | >512 | >128|
| 3985| 2006 | Kanto      | Feces            | D    | 357    | In991  | aacA7 | blαIMP-1 | blαOXA-2 | qacG | 256  | >512 | 256  | 8   | 64  | 128  | 16   |
| 4049| 2004 | Kyusyu     | Urine            | E    | 357    | In833  | blαIMP-1 | fosE | 2    | 64   | 64   | 4   | 32  | 8    | ≤0.25| 8    |
| No  | Year | Region | Site          | Gender | ID   | bla<sup>IMP</sup>-1 | aacA<sub>4</sub>'-3 | aacA<sub>1</sub> | aacA<sub>1</sub>, gcuG | aacA<sub>1</sub>, gcuG | aadA<sub>1</sub><sup>a</sup> | aadA<sub>2</sub> | bla<sup>VIM</sup>-2 | bla<sup>CEA</sup>-A7b | IPM | CAZ | PIPC | CFPM | CPFX |
|-----|------|--------|---------------|--------|------|----------------------|-------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|------|------|------|------|------|
| 4047 | 2004 | Kyusyu | Purulent discharge | F | 244 | In994 | 64 | 512 | 128 | 8 | 4 | >512 | 32 | >128 |
| 4048 | 2004 | Kyusyu | Purulent discharge | F | 244 | In994 | 64 | 512 | 128 | 8 | 4 | >512 | 32 | >128 |
| 4037 | 2004 | Kinki   | Urine         | F | 244 | In832 | 64 | 64 | 16 | 16 | >512 | 256 | 1 | 16 |
| 3980 | 2006 | Kyusyu | Urine         | G | 244 | In993 | 128 | >512 | 512 | 64 | 16 | 8 | 8 | <0.25 | 32 |
| 4028 | 2004 | Hokkaido | Urine       | H | 277 | In994 | 512 | >512 | 512 | 64 | 256 | 16 | 0.5 | >128 |
| 4030 | 2004 | Hokkaido | Urine       | H | 277 | In831 | 16 | >512 | >512 | 64 | >512 | >512 | 8 | 32 |
| 4027 | 2004 | Hokkaido | Sputum       | I | 186 | In830 | 32 | 512 | 128 | 16 | 4 | 128 | 8 | 8 |
| 3981 | 2006 | Kyusyu | Urine         | J | 175 | In827 | 512 | >512 | >512 | 128 | 256 | 128 | 4 | >128 |
| 3982 | 2006 | Kyusyu | Urine         | J | 175 | In827 | 512 | >512 | >512 | 128 | 256 | 128 | 4 | 32 |
| 3983 | 2006 | Kyusyu | Urine         | J | 175 | In827 | 512 | >512 | >512 | 128 | 256 | 128 | 4 | 32 |
| 4032 | 2004 | Kanto   | Blood         | J | 308 | In992 | 16 | >512 | 512 | 16 | 256 | 32 | 0.5 | 8 |
| 3987 | 2006 | Kyusyu | Urine         | K | 360 | In828 | 128 | 256 | 128 | 32 | 64 | 128 | 2 | 32 |

PFGE, pulsed-field gel electrophoresis; ST, sequence type; PIPC, piperacillin; CAZ, ceftazidime; CFPM, cefepime; AZT, aztreonam; IPM, imipenem; AMK, amikacin; ABK, arbekacin; CPFX, ciprofloxacin.

*3<sup>′</sup>-conserved segment (3<sup>'</sup>CS) was unknown and therefore no integron number was attributed.
bla<sub>IMP-6</sub> in In915, and bla<sub>IMP-10</sub> in In829) followed by accA28 and accA1a GCs. Similarly, thirteen isolates harbored In994-like integrons which contains a sole bla<sub>IMP-1</sub> group cassette (bla<sub>IMP-1</sub> in In994 and bla<sub>IMP-10</sub> in In995). The family of bla<sub>MBL</sub> genes and their position in integron GC arrays did not show significant differences in resistance profile (Table 2).

Genotypes and their relationship with integrons among MBL-producing <i>P. aeruginosa</i>

Among MBL-producing <i>P. aeruginosa</i> isolates, nine different STs were identified by MLST: the most prevalent was ST235 (17 isolates, 39%) followed by ST357 (14 isolates, 32%) and ST244 (4 isolates, 9%) (Table 2). While these major 3 STs were found both in 2004 and 2006, the other 6 STs were found either in 2004 or in 2006. Most integrons distributed in the specific genotypes of the isolates. In113-like integrons were found in ST235/pulsotype B isolates with significantly high frequency (13/13 vs 2/31; <i>P</i> < 0.0001), while partial bla<sub>IMP-7</sub>-harboring integron was exclusively found in ST235/pulsotype C (3/3 vs 0/41; <i>P</i> < 0.0001). While distributed across 5 geographic regions in total, ST235 was significantly associated with Kanto region (10/12 vs 7/32; <i>P</i> = 0.0003). ST235 was also associated with resistance to piperacillin (13/17 vs 7/27; <i>P</i> = 0.0017). Although not significant, a trend of increased ST235 in 2006 was observed (5/23 in 2004 vs 12/21 in 2006; <i>P</i> = 0.0291).

MBL-producing ST235 isolates seemed the dominant MDRP lineage in Japan as also reported worldwide [6,8-11,13]. As ST235 isolates are described as harboring a variety of resistance determinants including integrons, its diverse geographic distribution across Japan reflects part of the worldwide dissemination. Especially, isolates of ST235/pulsotype B with In113-like integron, recovered from 3 regions in the present study, were well characterized as a representative of the MDRP in Japan [15,16,19].

In our analysis, ST357 was significantly associated with In994-like integrons (11/14 vs. 3/30, <i>P</i> < 0.0001). ST357 is another widely disseminated lineage also found in the present study [4,7,16]. Concurrently, ST357 was found in Chugoku region with significantly high frequency (11/14 vs 3/30, <i>P</i> < 0.0001), which might possibly reflect local transmission. However, ST357 harbored 5 different integrons in total, including 2 with bla<sub>IMP-11</sub> group GCs emerged in 2006 (In826 and In991).

The significant association of specific genotypes and integrons implies that, in a relatively short period of time, dissemination and transmission of the preexisting resistant lineage, rather than horizontal gene transfer or recombination in situ, might largely explain their endemicity. Moreover, the genotypes of MBL-producers were unexpectedly similar to those in the central Europe with different resistant determinants, suggesting their possible advantage beyond other genotypes in the clinical settings [4]. Although the isolate number was small, the present study elucidated the emergence of ST357 isolates with novel integrons in distant geographic regions in 2006, as well as an emergence of the ST235/pulsotype C with partial integron harboring bla<sub>IMP-7</sub> in Kanto region, which might suggest the increased complexity of endemic lineages. In addition, isolates with ST175 was recovered in Kyushu with significantly higher frequency (3/3 vs 5/41, <i>P</i> = 0.0042).

One of the limitations of the present study is that this is retrospective in nature and therefore the results are not expected to be directly applied to the current clinical situation. There are also several reports in Japan addressing a variety of integron structures of <i>P. aeruginosa</i> [15-20], and they seemed to contain identical or similar integrons to ones identified in the current study. Nevertheless, the findings here are important, since most of the integron structures were novel to INTEGRALL database [12]; this could be explained by the lack of comprehensive platform for integron structure and nomenclature before the development of INTEGRALL database until recently. Alternatively, this might reflect true heterogeneity and diversity of the integrons among clinical isolates, especially among non-predominant lineages. Moreover, MLST comparison of cross-sectional nationwide survey is much informative for understanding of the dynamics of drug-resistant organisms. In addition, this is the first report of the presence of novel <i>fosI</i> gene cassette other than <i>Mycobacterium</i> spp. [26], and further analysis regarding the actual transfer route beyond the boundary of the species is warranted. As genotyping including MLST and INTEGRALL has been increasingly applied for tracking the development of the drug resistance rationally, the data in the present study would provide a robust baseline to estimate the current trend and future diversification of the drug-resistant lineages [20]. Another shortcoming of this study is that horizontal gene transfer of bla<sub>MBL</sub> genes, possibly located on plasmid or chromosome, was not experimentally addressed.

Conclusions

The current study offers an important “snapshot” of the molecular characteristics and dynamics of MBL-producing <i>P. aeruginosa</i> lineages including ST235 and ST357 across Japan and provide critical information for the design and implementation of surveillance programs targeted to the discovery of multidrug resistant <i>P. aeruginosa</i>.

Methods

Bacterial isolates

A total of 1,988 <i>P. aeruginosa</i> isolates (996 isolates in 2004 and 992 in 2006), were retrospectively collected as a part of nationwide surveillance programs in Japan.
(Japan Antimicrobial Resistance Surveillance Participants Group) [27,28]. Briefly, up to 10 non-duplicated patient isolates of 10 organism groups including *P. aeruginosa* were collected for three months in 2004 and in 2006 from a total of 100 institutions in 8 geographic regions. MBL-producers were phenotypically identified by the double-disk synergy test using ceftazidime (30 μg) and sodium mercaptoacetate (30 μg) disks (Eiken Chemical, Inc., Tokyo, Japan) following the manufacturer's instructions, and were subjected to further molecular epidemiological investigation [29]. Ethical approval has been obtained from Toho University School of Medicine Ethics Committee (2511925030).

**Antimicrobial susceptibility testing**

Minimum inhibitory concentrations (MICs) were measured by the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI) [30]. The antimicrobial agents tested were as follows: piperacillin sodium salt, ceftazidime hydrate, aztreonam, imipenem monohydrate, amikacin sulfate salt, ciprofloxacin hydrochloride monohydrate (Sigma-Aldrich Japan KK, Tokyo, Japan), cefepime hydrochloride (Bristol-Myers Squibb, Tokyo, Japan), and arbekacin sulfate salt (Meiji Seika Pharma Co., Ltd. Tokyo, Japan). The antimicrobial concentration ranges were 0.06 - 128 μg/ml except for ciprofloxacin (0.25 - 512 μg/ml). MICs were interpreted as susceptible (S), intermediate (I), or resistant (R) according to CLSI interpretive criteria where available [31].

MDRP was defined as strains with non-susceptibility to at least 1 agent in ≥3 antimicrobial categories according to the international expert proposal [32]; amikacin as aminoglycosides, imipenem as antipseudomonal carbapenems, ceftazidime or cefepime as antipseudomonal cephalosporins, aztreonam as monobactams.

**Analysis of MBL genes and integron by PCR amplification and nucleotide sequencing**

Genomic DNA was prepared by the Wizard genomic DNA preparation kit (Promega, Madison, WI, USA) according to the manufacturer's recommendations. PCR was performed with Takara ExTaq (Takara Bio, Shiga, Japan). Nucleotide sequencing was performed by a commercial DNA sequencing service (Greiner Bio-one, Tokyo, Japan). *bla*MBL genes were detected and identified by PCR and nucleotide sequencing using primers for *bla*IMP and *bla*VIM [33]. *bla*IMP-1, *bla*IMP-10, and *bla*IMP-6 are referred as *bla*IMP-1 group because the deduced amino acid sequences of *bla*IMP-1 differ by single amino acid from those of *bla*IMP-10 and *bla*IMP-6. Similarly, *bla*IMP-11 and *bla*IMP-41 are as *bla*IMP-11 group because the deduced amino acid sequences differ by single amino acid. Integrase genes specific for class 1, 2, or 3 integrons were detected by PCR using primers by Shibata *et al.* [33]. Integron GC arrays were determined by PCR and nucleotide sequencing by primer walking [34]. According to INTEGRALL nomenclature, novel completely sequenced GCs, namely from a part of 5′-conserved segment (5′CS) to a part of 3′-conserved segment (3′CS), were submitted to INTEGRALL for the attribution of new integron numbers [12].

**Genotyping**

MLST was performed as described by Curran *et al.* [3]. Pulsed-field gel electrophoresis (PFGE) of *SpeI*-digested DNA fragments from each strain was performed on a CHEF-MAPPER II apparatus (Bio Rad Laboratories, Rockland, Maine, USA) at 6 V/cm, for 19.7 h with pulse times running from 5.3 to 34.9 s in 0.5 × TBE buffer at 14°C. PFGE patterns in the dendrogram were analyzed with Molecular Analyst Software Fingerprinting II (Bio-Rad Laboratories). Only restriction fragments larger than 50 kb were used for analysis. PFGE genotypes were distinguished by the unweighted pair-group method using average linkages (UPGMA) and Dice coefficient, and isolates with ≥80% similarity were assigned into the same pulstype.

**Statistical analyses**

Statistical calculations were made using Graph-Pad Prism 5.01 (GraphPad Software Inc.). *P* values were calculated from two-tailed Fisher’s exact test for categorical variables, and *P* value <0.01 was considered as a statistically significant difference.

**Nucleotide sequences accession numbers for novel integrons**

Genbank/EMBL/DDBJ accession numbers for novel nucleotide sequences in the present study are as follows: AB901034-AB901041 for In826-In833, and AB901042-AB901046 for In991-995, and AB901047 for partial integron of isolate TUM3995.

**Competing interest**

The authors declare that they have no competing interests.

**Authors' contribution**

YM participated in the design of the study, carried out the experiments, and drafted the manuscript. TS participated in the design of the study, interpreted data, and revised the manuscript. YI conceived and designed the study, and revised the manuscript. AY participated in the design of the study, carried out the experiments, and drafted the manuscript. RAB, KY, and KT designed the study, and revised the manuscript. All authors read and approved the final manuscript.

**Authors' information**

YM, TS, YI, KY, and KT, are a Graduate Student, an Assistant Professor, a Professor, a Postdoctoral Researcher, an Emeritus Professor, and a Professor, respectively, at the Department of Microbiology and Infectious Diseases at Toho University in Tokyo, Japan. RAB is a Professor at the Departments of Medicine, Pharmacology, Molecular Biology and Microbiology at Case Western Reserve University School of Medicine as well as a Chief of Research.

---

Mano *et al.* BMC Microbiology (2015) 15:41
Service at Louis Stokes Cleveland Department of Veterans Affairs Medical Center in Cleveland, Ohio, the United States. TS, YL, RAB, KY, and KT are members of American Society for Microbiology (ASM).

Acknowledgement

The authors appreciated the technical supports and collaborations in the 100 hospitals. This work was supported by a grant from Bristol Myers KK, by a grant from Ministry of Health, Labor, and Welfare of Japan (No. H24-Shinkou-Japan-010 to KT), and by a grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 22591113 to YL). We appreciate Thomas Jovel at Université de Limoges for his crucial support of annotation and maintenance of INTEGRALL database. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers R01AI072219, and R01AI063517 to RAB. This study was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program Award 1I01BX001974 and the Geriatric Research Education and Clinical Center VISN 10 to RAB.

Author details

1Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan. Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Blvd., Cleveland, OH 44106, USA. 2Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.

Received: 22 August 2014 Accepted: 10 February 2015

Published online: 21 February 2015

References

1. Queenean AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20:440–58.
2. Pattridge SR, Tsafnat G, Coiera E, Iredell JR. Gene cassettes and cassette arrays in mobile resistance integrons. FEMS Microbiol Rev. 2009;33:757–84.
3. Cunran B, Jonas D, Grundmann H, Pitt T, Dowson CG. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol. 2004;42:5604–9.
4. Nemer A, Krizova L, Vascorovska M, Musilek M. Multidrug-resistant epidemic clones among bloodstream isolates of Pseudomonas aeruginosa in the Czech Republic. Res Microbiol. 2010;161:234–42.
5. Garcia-Castillo M, Del Campo R, Morosini MI, Riera E, Cabot G, Willems R, et al. Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-resistant Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J Clin Microbiol. 2011;49:2005–10.
6. Maataallah M, Chersia J, Backhouf A, Ivens A, Grundmann H, D’O. T, et al. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One. 2011;6:e25617.
7. Hrabak J, Cervena D, Izdebski R, Duljasz W, Gniadkowski M, Fridrichova M, et al. Outbreak of multiresistant epidemic carbapenem-resistant Pseudomonas aeruginosa ST235. PLoS One. 2011;6:e25617.
8. Ishii Y, Tateda K, Yamaguchi K. Evaluation of antimicrobial susceptibility for bacteria that grow aerobically -Ninth edition: approved standard M07-A9. Wayne, PA, USA: CLSI; 2012.
9. Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, et al. Detection of a phylogenetically distinct IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa isolate from a 100-hospital surveillance committee in Japan. J Clin Microbiol. 2013;51:1762–8.
10. Yoo JS, Yang JW, Kim HM, Byeon J, Kim HS, Yoo JI, et al. Dissemination of metallo-β-lactamase in Central Europe. J Clin Microbiol. 2011;49:2005–10.
11. Pournaras S, Kock R, Mossialos D, Mellmann A, Sakellaris V, Stathopoulos C, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2011;17:510–23.
12. Watanabe A, Yanagihara K, Matsumoto T, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2012;18:609–20.
13. Tsuij A, Kobayashi I, Oguri T, Inoue M, Yabuchii E, Goto S. An epidemiological study of the susceptibility and frequency of multiple-drug-resistant strains of Pseudomonas aeruginosa isolated at medical institutions nationwide in Japan. J Clin Microbiol. 2005;43:1164–70.
14. Yano H, Kuga A, Okamoto R, Inoue M, Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother. 2001;45:1343–8.
15. Arozoo H, Baba M, Takeda K, Yishi I, Oguri T, Okuzumi K, et al. In vitro combination effects of aztreonam and amoxicillin against multidrug-resistant Pseudomonas aeruginosa in Japan. Jpn J Infect Dis. 2012;65:83–7.
16. Leao SC, Matsumoto CK, Camerino A, Ramos RT, Nogueira CL, Lima JR, et al. The detection and sequencing of a broad-host-range conjugative IncP-1B plasmid in an epidemic strain of Mycobacterium abscessus subspecies boletii. PLoS One. 2013;8:e60746.
17. Yishi I, Alba J, Kimura S, Yamaguchi K. Evaluation of antimicrobial activity of β-lactam antibiotics by Etest against clinical isolates from 100 medical centers in Japan (2004). Diagn Microbiol Infect Dis. 2006;55:143–8.
18. Yishi I, Takeda K, Yamaguchi K. Evaluation of antimicrobial susceptibility for β-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). Diagn Microbiol Infect Dis. 2008;60:177–83.
19. Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, et al. Convenient test for screening metallo-β-lactamase-producing gram-negative bacteria by using thiold compounds. J Clin Microbiol. 2000;38:48–3.
20. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically -Ninth edition: approved standard M07-A9. Wayne, PA, USA: CLSI; 2012.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing -Twenty-second Informational Supplement M100-S22. Wayne, PA, USA: CLSI; 2012.
22. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant...
bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.

33. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, et al. PCR typing of genetic determinants for metallo-β-lactamases and integrons carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol. 2003;41:5407–13.

34. Martinez-Freijo P, Fluit AC, Schmitz FJ, Grek VS, Verhoef J, Jones ME. Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. J Antimicrob Chemother. 1998;42:689–96.